Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer Further Validation of a Potentially Practice-Changing Variable

被引：11
作者：
Ciombor, Kristen K.
Goldberg, Richard M. [1 ]
机构：
[1] Richard J Solove Res Inst, 460 W 10th Ave,Suite D920, Columbus, OH 43210 USA
来源：
JAMA ONCOLOGY | 2017年 / 3卷 / 02期
关键词：
1ST-LINE TREATMENT; PLUS CETUXIMAB; FLUOROURACIL; LEUCOVORIN; IRINOTECAN;
D O I：
10.1001/jamaoncol.2016.3777
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：165 / 166
页数：2
相关论文
共 12 条
[1]  
[Anonymous], J CLIN ONCOL S
[2]  
[Anonymous], J CLIN ONCOL S
[3]   The consensus molecular subtypes of colorectal cancer [J].
Guinney, Justin ;
Dienstmann, Rodrigo ;
Wang, Xin ;
de Reynies, Aurelien ;
Schlicker, Andreas ;
Soneson, Charlotte ;
Marisa, Laetitia ;
Roepman, Paul ;
Nyamundanda, Gift ;
Angelino, Paolo ;
Bot, Brian M. ;
Morris, Jeffrey S. ;
Simon, Iris M. ;
Gerster, Sarah ;
Fessler, Evelyn ;
Melo, Felipe De Sousa E. ;
Missiaglia, Edoardo ;
Ramay, Hena ;
Barras, David ;
Homicsko, Krisztian ;
Maru, Dipen ;
Manyam, Ganiraju C. ;
Broom, Bradley ;
Boige, Valerie ;
Perez-Villamil, Beatriz ;
Laderas, Ted ;
Salazar, Ramon ;
Gray, Joe W. ;
Hanahan, Douglas ;
Tabernero, Josep ;
Bernards, Rene ;
Friend, Stephen H. ;
Laurent-Puig, Pierre ;
Medema, Jan Paul ;
Sadanandam, Anguraj ;
Wessels, Lodewyk ;
Delorenzi, Mauro ;
Kopetz, Scott ;
Vermeulen, Louis ;
Tejpar, Sabine .
NATURE MEDICINE, 2015, 21 (11) :1350-1356
[4]   FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].
Heinemann, Volker ;
von Weikersthal, Ludwig Fischer ;
Decker, Thomas ;
Kiani, Alexander ;
Vehling-Kaiser, Ursula ;
Al-Batran, Salah-Eddin ;
Heintges, Tobias ;
Lerchenmueller, Christian ;
Kahl, Christoph ;
Seipelt, Gernot ;
Kullmann, Frank ;
Stauch, Martina ;
Scheithauer, Werner ;
Hielscher, Joerg ;
Scholz, Michael ;
Mueller, Sebastian ;
Link, Hartmut ;
Niederle, Norbert ;
Rost, Andreas ;
Hoeffkes, Heinz-Gert ;
Moehler, Markus ;
Lindig, Reinhard U. ;
Modest, Dominik P. ;
Rossius, Lisa ;
Kirchner, Thomas ;
Jung, Andreas ;
Stintzing, Sebastian .
LANCET ONCOLOGY, 2014, 15 (10) :1065-1075
[5]  
Lee MS, 2016, J CLIN ONCOL S, V34
[6]   Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features [J].
Missiaglia, E. ;
Jacobs, B. ;
D'Ario, G. ;
Di Narzo, A. F. ;
Soneson, C. ;
Budinska, E. ;
Popovici, V. ;
Vecchione, L. ;
Gerster, S. ;
Yan, P. ;
Roth, A. D. ;
Klingbiel, D. ;
Bosman, F. T. ;
Delorenzi, M. ;
Tejpar, S. .
ANNALS OF ONCOLOGY, 2014, 25 (10) :1995-2001
[7]   Fluorouracil modulation in colorectal cancer:: Lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule -: An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B study [J].
O'Dwyer, PJ ;
Manola, J ;
Valone, FH ;
Ryan, LM ;
Hines, JD ;
Wadler, S ;
Haller, DG ;
Arbuck, SG ;
Weiner, LM ;
Mayer, RJ ;
Benson, AB .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2413-2421
[8]  
Schrag D, 2016, J CLIN ONCOL S, V34
[9]   Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials [J].
Tejpar, Sabine ;
Stintzing, Sebastian ;
Ciardiello, Fortunato ;
Tabernero, Josep ;
Van Cutsem, Eric ;
Beier, Frank ;
Esser, Regina ;
Lenz, Heinz-Josef ;
Heinemann, Volker .
JAMA ONCOLOGY, 2017, 3 (02) :194-201
[10]   Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer [J].
Van Cutsem, Eric ;
Lenz, Heinz-Josef ;
Koehne, Claus-Henning ;
Heinemann, Volker ;
Tejpar, Sabine ;
Melezinek, Ivan ;
Beier, Frank ;
Stroh, Christopher ;
Rougier, Philippe ;
van Krieken, J. Han ;
Ciardiello, Fortunato .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07) :692-700
12